z-logo
Premium
Synthesis of [ 3 H] vardenafil, Levitra ® , using a new labeling technique
Author(s) -
Pleiss U.
Publication year - 2003
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.782
Subject(s) - chemistry , vardenafil , radiochemistry , specific activity , lithium (medication) , tritium , amide , aluminum hydride , nuclear chemistry , stereochemistry , enzyme , organic chemistry , sildenafil , tadalafil , medicine , physics , nuclear physics , catalysis , endocrinology , methoxide
Tritium was introduced into the new orally active, selective phosphodiesterase type V (PDE V) inhibitor vardenafil (Levitra ® ), by reduction of a suitable amide precursor with freshly prepared lithium aluminum tritide. A specific activity of 52.7 Ci/mmol (1.95 TBq/mmol) was achieved. In order to overcome the usual technical difficulties during the preparation of complex tritides a new and easy labeling technique which has considerable potential for various tritia‐tion procedures, was developed. Copyright © 2003 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom